Literature DB >> 29582086

Applicability of Publicly Reported Hospital Readmission Measures to Unreported Conditions and Other Patient Populations: A Cross-sectional All-Payer Study.

Neel M Butala1, Daniel B Kramer2, Changyu Shen2, Jordan B Strom2, Kevin F Kennedy3, Yun Wang4, Linda R Valsdottir2, Jason H Wasfy1, Robert W Yeh2.   

Abstract

Background: Readmission rates after hospitalizations for heart failure (HF), acute myocardial infarction (AMI), and pneumonia among Medicare beneficiaries are used to assess quality and determine reimbursement. Whether these measures reflect readmission rates for other conditions or insurance groups is unknown. Objective: To investigate whether hospital-level 30-day readmission measures for publicly reported conditions (HF, AMI, and pneumonia) among Medicare patients reflect those for Medicare patients hospitalized for unreported conditions or non-Medicare patients hospitalized with HF, AMI, or pneumonia. Design: Cross-sectional. Setting: Population-based. Participants: Hospitals in the all-payer Nationwide Readmissions Database in 2013 and 2014. Measurements: Hospital-level 30-day all-cause risk-standardized excess readmission ratios (ERRs) were compared for 3 groups of patients: Medicare beneficiaries admitted for HF, AMI, or pneumonia (Medicare reported group); Medicare beneficiaries admitted for other conditions (Medicare unreported group); and non-Medicare beneficiaries admitted for HF, AMI, or pneumonia (non-Medicare group).
Results: Within-hospital differences in ERRs varied widely among groups. Medicare reported ratios differed from Medicare unreported ratios by more than 0.1 for 29% of hospitals and from non-Medicare ratios by more than 0.1 for 46% of hospitals. Among hospitals with higher readmission ratios, ERRs for the Medicare reported group tended to overestimate ERRs for the non-Medicare group but underestimate those for the Medicare unreported group. Limitation: Medicare groups and risk adjustment differed slightly from those used by the Centers for Medicare & Medicaid Services.
Conclusion: Hospital ERRs, as estimated by Medicare to determine financial penalties, have poor agreement with corresponding measures for populations and conditions not tied to financial penalties. Current publicly reported measures may not be good surrogates for overall hospital quality related to 30-day readmissions. Primary Funding Source: Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.

Entities:  

Mesh:

Year:  2018        PMID: 29582086     DOI: 10.7326/M17-1492

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  5 in total

1.  Patient Readmission Rates For All Insurance Types After Implementation Of The Hospital Readmissions Reduction Program.

Authors:  Enrico G Ferro; Eric A Secemsky; Rishi K Wadhera; Eunhee Choi; Jordan B Strom; Jason H Wasfy; Yun Wang; Changyu Shen; Robert W Yeh
Journal:  Health Aff (Millwood)       Date:  2019-04       Impact factor: 6.301

2.  Suitability of elderly adult hospital readmission rates for profiling readmissions in younger adult and pediatric populations.

Authors:  Emily M Bucholz; Sara L Toomey; Neel M Butala; Alyna T Chien; Robert W Yeh; Mark A Schuster
Journal:  Health Serv Res       Date:  2020-02-09       Impact factor: 3.402

3.  Publicly Reported Readmission Measures and the Hospital Readmissions Reduction Program: A False Equivalence?

Authors:  Rohan Khera; Leora I Horwitz; Zhenqiu Lin; Harlan M Krumholz
Journal:  Ann Intern Med       Date:  2018-03-27       Impact factor: 25.391

4.  Association of Inclusion of Medicare Advantage Patients in Hospitals' Risk-Standardized Readmission Rates, Performance, and Penalty Status.

Authors:  Orestis A Panagiotou; Kirsten R Voorhies; Laura M Keohane; Daeho Kim; Deepak Adhikari; Amit Kumar; Maricruz Rivera-Hernandez; Momotazur Rahman; Pedro Gozalo; Roee Gutman; Vincent Mor; Amal N Trivedi
Journal:  JAMA Netw Open       Date:  2021-02-01

5.  Association of Continuity of Care With Outcomes in US Veterans With Inflammatory Bowel Disease.

Authors:  Shirley Cohen-Mekelburg; Sameer D Saini; Sarah L Krein; Timothy P Hofer; Beth I Wallace; John M Hollingsworth; Julie P W Bynum; Wyndy Wiitala; Jennifer Burns; Peter D R Higgins; Akbar K Waljee
Journal:  JAMA Netw Open       Date:  2020-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.